Opening New Possibilities in Ocular Drug Delivery: EyeLief® and OcuLief®
Thu, Oct 29
|
03:00 PM - 03:15 PM
Fairfax
Session details:
Transforming Anti-VEGF Delivery
What would fewer injections mean for patient compliance, clinic workload, and overall treatment outcomes? In this session, Dr Ruane will present:
- How Re-Vana’s sustained-release technology could reduce injection frequency for patients with retinal diseases.
- The science behind Re-Vana’s biodegradable implants and why it matters for the future of ophthalmology.
- Potential paths forward, clinical development, partnerships, and commercial strategy.
